Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
Clinical trial NCT04213209 · COMPLETED
Trial details
- NCT number
- NCT04213209
- Sponsor
- Takeda
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2020-02-14
- Primary completion
- 2023-12-13
- Enrollment
- 95
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.